Skip navigationEnd of navigation

Guidance for COVID-19 from DCP

March 19, 2020

Due to concerns regarding the spread of COVID-19 and the impact it is having on hospitals, clinics, physician offices, and clinical trial participants’ ability to travel, the NCI, DCP is providing clarification on measures to address some of the current challenges in providing care to participants enrolled on clinical trials in order to mitigate immediate hazards to the patients.

Guidance is also provided for identifying and reporting COVID-19 related Adverse and Serious Adverse Events, as well as minor deviations which are to be reported on the COVID Minor Deviation Reporting Form.

Please refer to the DCP-issued memorandums regarding COVID-19 for the latest information.

‹ Back to News

Recent News

September 13, 2021

ODP Seeking Nominations for 2022 Early Stage Investigator Lecture

September 09, 2021

CASCADE Funding Opportunities

Learn more about CP-CTNet on the National Cancer Institute website

This project is supported by the National Cancer Institute (NCI) of the National Institutes of Health under award number U24CA242637. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.

Copyright © 2021, Frontier Science and Technology Research Foundation, Inc. All rights reserved.

Privacy and Terms of Use